Literature DB >> 6955632

HLA and heterogeneity of multiple sclerosis.

T Engell, N E Raun, M Thomsen, P Platz.   

Abstract

Age at onset, debut symptoms, optic nerve signs, and severity of symptoms were evaluated from the medical records of 135 patients with MS. HLA-D/DR2 was significantly more frequent in rapidly progressive MS, and D/DR2 seemed to confer both susceptibility to the disease and to more rapid progression. However, D/DR3 seemed to protect against rapid progression.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6955632     DOI： 10.1212/wnl.32.9.1043

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  6 in total

1.  HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.

Authors:  A E Hensiek; S J Sawcer; R Feakes; J Deans; A Mander; E Akesson; R Roxburgh; F Coraddu; S Smith; D A S Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

2.  An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus.

Authors:  G C DeLuca; S V Ramagopalan; B M Herrera; D A Dyment; M R Lincoln; A Montpetit; M Pugliatti; M C N Barnardo; N J Risch; A D Sadovnick; M Chao; S Sotgiu; T J Hudson; G C Ebers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-17       Impact factor: 11.205

3.  HLA and prognosis in multiple sclerosis.

Authors:  B Runmarker; T Martinsson; J Wahlström; O Andersen
Journal:  J Neurol       Date:  1994-05       Impact factor: 4.849

4.  Expression of the human histocompatibility leukocyte antigen DR3 transgene reduces the severity of demyelination in a murine model of multiple sclerosis.

Authors:  K M Drescher; L T Nguyen; V Taneja; M J Coenen; J L Leibowitz; G Strauss; G J Hammerling; C S David; M Rodriguez
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

5.  Multiple sclerosis: genetic versus environmental aetiology: epidemiology in Israel updated.

Authors:  E Kahana; N Zilber; J H Abramson; V Biton; Y Leibowitz; O Abramsky
Journal:  J Neurol       Date:  1994-03       Impact factor: 4.849

6.  Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon β-1a.

Authors:  Shlomo Flechter; Tirza Klein; Lea Pollak
Journal:  Neurol Int       Date:  2011-06-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.